WP
VYGR icon

Woodline Partners’s Voyager Therapeutics VYGR Stock Holding History

Woodline Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-193,984
Closed -$749K – 1156
2026
Q1 		$749K Buy
+193,984
New +$764K ﹤0.01% 914
2024
Q3 		– Sell
-300,000
Closed -$2.37M – 714
2024
Q2 		$2.37M Hold
300,000
– – 0.02% 408
2024
Q1 		$2.79M Buy
+300,000
New +$2.53M 0.03% 410

Other funds holding VYGR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Woodline Partners's VYGR Position: Q2 2026 in Review

Woodline Partners sold out of Voyager Therapeutics (VYGR) in Q2 2026, closing a stake of 193,984 shares — an estimated $749K sold.

Woodline Partners first reported a position in VYGR in Q1 2024 and held it in 3 quarters. The position peaked at $2.79M in Q1 2024. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.

  • Woodline Partners reported no remaining Voyager Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Woodline Partners sold 193,984 Voyager Therapeutics shares in Q2 2026, an estimated $749K.
  • Woodline Partners first reported a position in Voyager Therapeutics in Q1 2024 and held it in 3 quarters.
  • Woodline Partners's Voyager Therapeutics position peaked at $2.79M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.